Jose Conejo-Garcia
@conejo-garcia.bsky.social
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
Press Releases :: Anixa Biosciences, Inc. (ANIX)
ir.anixa.com
November 17, 2025 at 1:44 PM
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
The promise of TIL therapy for glioblastoma.
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
The promise of TIL therapy for glioblastoma
Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presen…
www.sciencedirect.com
November 14, 2025 at 12:50 AM
The promise of TIL therapy for glioblastoma.
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT)
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: Fireside Chat: Anixa Biosciences, Inc. (ANIX) . After registering, you will receive a confirmation email about joining the webinar.
Please join us for a conversation with Chairman & CEO Dr. Amit Kumar, PhD, on Tuesday, November 11, 2025, at 2:00 pm ET. Our topics of discussion will cover:
• An overview of clinical development pro...
us06web.zoom.us
November 10, 2025 at 4:38 PM
Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT)
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy
Depletion of the ER stress sensor IRE1α can reduce paclitaxel-induced peripheral neuropathy in mice.
www.science.org
November 3, 2025 at 9:28 PM
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...
Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"):
www.science.org/content/arti...
www.science.org/content/arti...
Medicine Nobel for researchers who discovered immune system's security guards
Mary Brunkow, Fred Ramsdell, Shimon Sakaguchi honored for research on ‘peripheral immune tolerance’
www.science.org
October 6, 2025 at 10:19 AM
Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"):
www.science.org/content/arti...
www.science.org/content/arti...
working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer ...
Abstract. Endometrial cancer is now the leading cause of gynecologic cancer death in the United States. Recognizing the urgent need to improve outcomes for
academic.oup.com
September 11, 2025 at 7:11 PM
working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
August 12, 2025 at 1:44 PM
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
Immune memory shapes ovarian cancer recurrence:
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Immune memory shapes ovarian cancer recurrence
Despite current progress, many patients with ovarian cancer (OC) often relapse after
therapy. In this issue of Cancer Cell, Ghisoni et al. integrate multiomic and functional
analyses to provide a road...
www.cell.com
August 11, 2025 at 4:47 PM
Immune memory shapes ovarian cancer recurrence:
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas.
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
August 8, 2025 at 2:18 PM
Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas.
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Ghisoni et al. profile the immune landscape of 697 ovarian cancers (OCs), identifying
four immune phenotypes linked to prognosis and treatment response. The study demonstrates
that BRCA-dependent TIL:...
www.cell.com
July 31, 2025 at 3:26 PM
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...
Federal government freezes $108 million in NIH funding to Duke, source tells The Chronicle
The freeze follows two federal investigations launched Monday by the Trump administration into Duke University and Duke Health, alleging “systemic racial discrimination” and violations of the Civil Ri...
www.dukechronicle.com
July 31, 2025 at 11:14 AM
Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...
In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity:
rdcu.be/exGyT
rdcu.be/exGyT
Humoral determinants of checkpoint immunotherapy
Nature - Rapid extracellular antibody profiling reveals a contribution of autoantibodies to the effectiveness of checkpoint immunotherapy for cancer.
rdcu.be
July 24, 2025 at 6:11 PM
In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity:
rdcu.be/exGyT
rdcu.be/exGyT
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing
The successful treatment of melanoma using autologous in-vitro expanded tumor infiltrating
lymphocytes (TILs) has sparked clinical trials for the assessment of TILs efficacy
against other cancers, inc...
www.isct-cytotherapy.org
July 9, 2025 at 3:18 PM
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...
NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...
NIH announces end to funding for animal-only studies - Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
www.drugdiscoverytrends.com
July 8, 2025 at 12:49 PM
NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...
Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84:
www.timesofisrael.com/zelig-eshhar...
www.timesofisrael.com/zelig-eshhar...
Zelig Eshhar, leading cancer researcher and immunologist, dies at 84
Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for $12 billion in 2017
www.timesofisrael.com
July 7, 2025 at 7:10 PM
Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84:
www.timesofisrael.com/zelig-eshhar...
www.timesofisrael.com/zelig-eshhar...
Great article from Tao wang in Nature Cancer:
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes - Nature Cancer
Song et al. developed a computational tool to profile binding pairs between tumor-derived antigens and antibodies from high-throughput B cell receptor sequencing data, predicting response to immune-ch...
www.nature.com
June 30, 2025 at 10:39 PM
Great article from Tao wang in Nature Cancer:
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
Reposted by Jose Conejo-Garcia
Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors.
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
June 26, 2025 at 11:44 AM
Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors.
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort.
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
Press Releases :: Anixa Biosciences, Inc. (ANIX)
ir.anixa.com
June 23, 2025 at 1:40 PM
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort.
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
Reposted by Jose Conejo-Garcia
Hear from OCRP leaders in this video series on how the Ovarian Cancer Academy supports researchers in making ovarian cancer the focus of their scientific careers and accelerating progress in the field:
www.youtube.com/watch?v=rC2G...
www.youtube.com/watch?v=ogO4...
www.youtube.com/watch?v=DwWV...
www.youtube.com/watch?v=rC2G...
www.youtube.com/watch?v=ogO4...
www.youtube.com/watch?v=DwWV...
OCRP Academy Video Preview 28Feb
YouTube video by CDMRP
www.youtube.com
June 10, 2025 at 6:34 PM
Hear from OCRP leaders in this video series on how the Ovarian Cancer Academy supports researchers in making ovarian cancer the focus of their scientific careers and accelerating progress in the field:
www.youtube.com/watch?v=rC2G...
www.youtube.com/watch?v=ogO4...
www.youtube.com/watch?v=DwWV...
www.youtube.com/watch?v=rC2G...
www.youtube.com/watch?v=ogO4...
www.youtube.com/watch?v=DwWV...
Dr. Roger Li receives the Young Investigator Award of the Society of Urologic Oncology.
I cannot imagine a more deserved prize.
Congratulations, Roger!
suonet.org/awards/young...
I cannot imagine a more deserved prize.
Congratulations, Roger!
suonet.org/awards/young...
Young Investigator Award :: Society of Urologic Oncology
The mission of the Society of Urologic Oncology (SUO) is to enable qualified members primarily interested in the care of patients with malignant GU diseases to meet for the purpose of discussion, deve...
suonet.org
June 2, 2025 at 9:33 PM
Dr. Roger Li receives the Young Investigator Award of the Society of Urologic Oncology.
I cannot imagine a more deserved prize.
Congratulations, Roger!
suonet.org/awards/young...
I cannot imagine a more deserved prize.
Congratulations, Roger!
suonet.org/awards/young...
Reposted by Jose Conejo-Garcia
Anixa Biosciences Outlines Significant Progress and Key Milestones in Shareholder Letter#United_States#Anixa_Biosciences#San_Jose#CAR-T_therapy#Breast_Cancer_Vaccine
Anixa Biosciences Outlines Significant Progress and Key Milestones in Shareholder Letter
Anixa Biosciences, under CEO Dr. Amit Kumar, shares substantial progress in cancer treatments and plans for 2025 in a recent letter to shareholders.
third-news.com
May 19, 2025 at 12:19 PM
Anixa Biosciences Outlines Significant Progress and Key Milestones in Shareholder Letter#United_States#Anixa_Biosciences#San_Jose#CAR-T_therapy#Breast_Cancer_Vaccine
Excited to help show biology of TIL cell therapy resistance in lung cancer!
Important findings in real world samples:
>Missing neoantigens at progression
>Failure of persistence of antigen-specific clones
>HLA LOH
www.nature.com/articles/s43...
Important findings in real world samples:
>Missing neoantigens at progression
>Failure of persistence of antigen-specific clones
>HLA LOH
www.nature.com/articles/s43...
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy - Nature Cancer
Wang et al. present T cell receptor sequencing of serial tumor and blood samples from TIL-treated patients with non-small cell lung cancer, identifying tumor-reactive clonotypes expressing dysfunction...
www.nature.com
May 8, 2025 at 3:31 PM
Excited to help show biology of TIL cell therapy resistance in lung cancer!
Important findings in real world samples:
>Missing neoantigens at progression
>Failure of persistence of antigen-specific clones
>HLA LOH
www.nature.com/articles/s43...
Important findings in real world samples:
>Missing neoantigens at progression
>Failure of persistence of antigen-specific clones
>HLA LOH
www.nature.com/articles/s43...
New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates ocrahope.org/news/new-glo...
New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab
Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft’s AI for Good Lab to supercharge the next cancer research breakt...
ocrahope.org
May 8, 2025 at 3:28 PM
New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates ocrahope.org/news/new-glo...
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology.
The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer.
Trial ongoing with more results coming soon.
ir.anixa.com/press-releas...
The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer.
Trial ongoing with more results coming soon.
ir.anixa.com/press-releas...
Press Releases :: Anixa Biosciences, Inc. (ANIX)
ir.anixa.com
April 14, 2025 at 1:00 PM
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology.
The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer.
Trial ongoing with more results coming soon.
ir.anixa.com/press-releas...
The treatment is so far safe in all patients and effective in a subset of patients with recurrent ovarian cancer.
Trial ongoing with more results coming soon.
ir.anixa.com/press-releas...
What Is Actually the Point of Treating the N.I.H. Like This? www.nytimes.com/2025/04/11/o...
Opinion | What Is Actually the Point of Treating the N.I.H. Like This?
Efficiency is not being enhanced, nor is waste being eliminated at the N.I.H. Scientists are just left to wonder: Why?
www.nytimes.com
April 11, 2025 at 6:52 PM
What Is Actually the Point of Treating the N.I.H. Like This? www.nytimes.com/2025/04/11/o...